Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1038/s41467-021-27097-8

http://scihub22266oqcxt.onion/10.1038/s41467-021-27097-8
suck pdf from google scholar
34815389!8610983!34815389
unlimited free pdf from europmc34815389    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid34815389      Nat+Commun 2021 ; 12 (1): 6791
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury #MMPMID34815389
  • Yamaguchi T; Hoshizaki M; Minato T; Nirasawa S; Asaka MN; Niiyama M; Imai M; Uda A; Chan JF; Takahashi S; An J; Saku A; Nukiwa R; Utsumi D; Kiso M; Yasuhara A; Poon VK; Chan CC; Fujino Y; Motoyama S; Nagata S; Penninger JM; Kamada H; Yuen KY; Kamitani W; Maeda K; Kawaoka Y; Yasutomi Y; Imai Y; Kuba K
  • Nat Commun 2021[Nov]; 12 (1): 6791 PMID34815389show ga
  • Angiotensin-converting enzyme 2 (ACE2) is a receptor for cell entry of SARS-CoV-2, and recombinant soluble ACE2 protein inhibits SARS-CoV-2 infection as a decoy. ACE2 is a carboxypeptidase that degrades angiotensin II, thereby improving the pathologies of cardiovascular disease or acute lung injury. Here we show that B38-CAP, an ACE2-like enzyme, is protective against SARS-CoV-2-induced lung injury. Endogenous ACE2 expression is downregulated in the lungs of SARS-CoV-2-infected hamsters, leading to elevation of angiotensin II levels. Recombinant Spike also downregulates ACE2 expression and worsens the symptoms of acid-induced lung injury. B38-CAP does not neutralize cell entry of SARS-CoV-2. However, B38-CAP treatment improves the pathologies of Spike-augmented acid-induced lung injury. In SARS-CoV-2-infected hamsters or human ACE2 transgenic mice, B38-CAP significantly improves lung edema and pathologies of lung injury. These results provide the first in vivo evidence that increasing ACE2-like enzymatic activity is a potential therapeutic strategy to alleviate lung pathologies in COVID-19 patients.
  • |*COVID-19 Drug Treatment[MESH]
  • |Acute Lung Injury[MESH]
  • |Angiotensin II[MESH]
  • |Angiotensin-Converting Enzyme 2/*metabolism[MESH]
  • |Animals[MESH]
  • |COVID-19/pathology/*prevention & control[MESH]
  • |Carboxypeptidases[MESH]
  • |Chlorocebus aethiops[MESH]
  • |Cricetinae[MESH]
  • |Disease Models, Animal[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Lung Injury/*prevention & control[MESH]
  • |Lung/pathology[MESH]
  • |Male[MESH]
  • |Mice[MESH]
  • |Mice, Transgenic[MESH]
  • |Pulmonary Edema/pathology/prevention & control[MESH]
  • |SARS-CoV-2/*drug effects[MESH]
  • |Spike Glycoprotein, Coronavirus/drug effects[MESH]
  • |Vero Cells[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box